Amgen profits rise, next MariTide studies start by mid-year
Amgen posted a higher quarterly profit on Tuesday as product sales rose 11% and said late-stage studies of key obesity drug ...
FierceBiotech6d
Amgen's early-stage obesity asset slapped with FDA hold
Amgen’s mysterious obesity asset will remain a mystery for a bit longer—the FDA has put the candidate’s phase 1 trial ...
BioSpace6d
Pipeline Problems Mar Amgen’s Q4 Beat
Amgen outperformed expectations in the fourth quarter of 2024, but revealed an FDA hold on early-stage obesity asset AMG 513 ...
STAT6d
Study of Amgen’s early obesity candidate paused by FDA
The company said the agency's hold was "not related to the drug,” dubbed AMG 513, and that discussions were underway to ...
Amgen Q4 Earnings: Good Quarter, Ok Guidance, But MariTide Concerns Me (Rating Downgrade)
Amgen's Q4 2024 earnings show a 19% revenue increase year-on-year, with non-GAAP EPS up 13% in Q4 and 6% for the full year.
Amgen says Phase 1 AMG 513 obesity study placed on clinical hold by FDA
Amgen (AMGN) provided updates on selected product and pipeline programs, including that a Phase 1 study of AMG 513 in people living with ...
Yahoo Finance6d
Amgen profits rise, next MariTide studies start by mid-year
(Reuters) - Amgen ... for MariTide, which activates the appetite- and blood sugar-reducing hormone known as GLP-1 while blocking a second gut hormone called GIP. The drug, given by injection ...
Yahoo Finance6d
Amgen profit beats estimates, next MariTide studies start by mid-year
Amgen investors have been focused on prospects for MariTide, which activates the appetite- and blood sugar-reducing hormone known as GLP-1 while blocking a second gut hormone called GIP. The drug, ...
Yahoo Finance6d
Amgen profits rise, next MariTide studies start by mid-year
Amgen investors are focused on prospects for MariTide, which activates the appetite- and blood sugar-reducing hormone known as GLP-1 while blocking a second gut hormone called GIP. The drug, given by ...